Financial & competing interests disclosure
This commentary has not received any financial support. F Rico-Villademoros has served as freelance consultant for Almirall, AstraZeneca, Eli Lilly, GSK, Lundbeck, Pfizer, Roche and Sanofi-Aventis. The authors have no other relevant affiliations or financial involvement with any organization with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
The commentary has been reviewed by a professional English language-editing company (American Journal Experts); this service has been funded by the authors.